Among BCs, MUC-1 is most common in HER2+ cases: it is expressed in 87.5% of HER2+ BC cases, compared to 60.7%, 68.8%, and 56.6% of LumA, LumB, and TNBC cases, respectively [151]. Here, MUC1 is linked to breast cancer.